Policy Guide: China's Healthcare Payment System

I. Framework of China's Healthcare Payment System

China's healthcare payment system operates under government-guided pricing, forming a "triple-layer protection" mechanism comprising basic medical insurance, individual out-of-pocket payments, and commercial insurance. All public hospitals strictly implement provincial Medical Service Price Catalogs, ensuring uniform pricing for identical services within each province. Core characteristics:

• Mandatory government pricing: provincial healthcare security bureaus issue unified price lists (e.g., appendectomy: ¥6,800 in Shanghai vs. ¥4,200 in Henan).
• Hospitals have no pricing autonomy; violations incur 5× fines (Price Law Article 39).

Multi-layer payment structure:

• Basic insurance pool: 100% for Category A drugs; 50–70% for Category B (~70% of total).
• Individual out-of-pocket: deductibles + non-reimbursable drugs + copay (16–45%).
• Commercial insurance: secondary reimbursement for out-of-pocket costs (5–15%).

Payment reform trajectory: a transition from fee-for-service to value-based DRG/DIP prepayment systems, with nationwide 2.0 grouping standards effective 2025.

II. Basic Insurance Fund Payment: Primary Support

• Catalog control: reimbursement is limited to items in the Drug/Procedure/Medical Facility Catalogs — Category A drugs reimbursed 100%; Category B drugs with partial copay (e.g., 10% patient copay on a ¥100 drug → ¥90 covered).
• Phased reimbursement: deductibles apply (outpatient: ¥300–1,200; inpatient: ¥800–1,500); annual reimbursement caps are typically ¥200,000–300,000.
• Coverage: implemented in 393 regions (191 DRG + 200 DIP), covering 95% of diseases and 80% of insurance funds.

Mechanisms:

• DRG: fixed prepayment per diagnosis group (e.g., ¥6,000 for pneumonia regardless of actual cost).
• DIP: dynamic payment adjustment based on disease complexity scoring.

Outcomes: 10% slower insurance expenditure growth; 15% reduction in per-admission costs.

Pre-reform: 60-day reimbursement delay → Post-reform: Anhui pays 60% in advance on discharge day, with monthly settlement in 1 day (releasing ¥17B in liquidity in 2024); Hainan pays within 24 hours of claim submission.

III. Individual Out-of-Pocket Payments: Direct Burden

Patient payments comprise three components, influenced by insurance type and region:

• Deductible: a fixed amount (inpatient: ¥800–1,500). Full self-pay applies if expenses fall below the threshold.
• Copay rate: (catalog cost − deductible) × rate (10%–40%). Example: 15% copay for urban employees at Shanghai Tier-3 hospitals.
• Non-reimbursable items: off-catalog drugs, premium services. Example: targeted therapy drugs exceeding ¥10,000/month.

Support policies: "Treatment Before Payment" — poverty-stricken patients are exempt from deposits (Jinzhai County, Anhui); One-Stop Settlement — basic insurance + critical illness insurance + medical aid integrated (Changyang County, Hubei).

IV. Commercial Supplementary Insurance: Secondary Protection

• Gap coverage: reimburses non-covered expenses (e.g., Shandong University student insurance: ¥30,000 drug coverage).
• Claim requirement: basic insurance settlement must precede claims (otherwise reimbursement drops to 60–70%).

Main types:

• Million-Yuan Medical: for catastrophic costs; ¥10,000 deductible → 100% beyond it.
• Hui Min Bao: pre-existing conditions accepted; e.g., Shanghai "Hu Hui Bao": ¥129/year, 70% specialty drug coverage.
• Specialized plans: IVF/dental services; e.g., IVF installment: 30% down + 12 months.

Difficulties: document complexity (requires original invoices + medical records + insurance settlement slips — 5+ documents); delayed processing (academic-year policies cause a Sep–Apr claims backlog, as in Shandong University cases).

V. Private Hospital Premium Care: Market-Driven Pricing

Private institutions provide non-insurance-covered premium services under a distinct payment logic:

• IVF: ¥40,000–80,000/cycle (vs. ¥20,000–40,000 in public) → installment payments common.
• Premium clinics: registration fees ¥500–2,000 (vs. public: ¥50–100) → commercial insurance direct billing.
• International departments: C-section package ¥80,000 (Beijing) → full self-pay or insurance settlement.

Regulation & risks: prices must be publicly filed (though not government-controlled); overtreatment concerns (e.g., non-essential tests such as genetic screening packages).

VI. Challenges & Reform Directions

• Regional disparity: Shanghai inpatient copay 16% vs. Hebei rural 45%.
• Catalog lag: innovative drugs take an average of 14 months to enter catalogs (e.g., PD-1 inhibitors).
• Insurance fraud: ¥5.3B in fraudulent claims detected in 2024.

Reform directions: direct pharma settlement (insurers pay manufacturers directly; Inner Mongolia pilot: 30-day payment cycle); DRG 2.0 upgrade (409 core + 634 subgroup refinements, plus new gene therapy categories); AI oversight (Hainan's system detects 17 fraud types, blocking ¥530M in 2024).

China–US–UK Payment System Comparison

• Pricing authority: China — provincial governments; USA — hospital-insurer negotiations; UK (NHS) — central government.
• Patient burden: China — average inpatient copay ¥2,500; USA — average $3,100 (~¥22,000) per admission; UK — £0 (but months-long waits).
• Innovation incentive: China — DRG surplus retention; USA — patent-drug premium mechanisms; UK — budget caps limit new tech.
• Equity gap: China — 30%+ urban-rural reimbursement disparity; USA — the uninsured face catastrophic bills; UK — private queue-jumping.

Conclusion: Coordinated Evolution of a Multi-Layer System

China's payment system is transitioning from volume expansion to value-based care under rigid government pricing:

• Base layer (insurance): DRG/DIP cost control → province-level "zero-delay" settlement by 2025.
• Supplementary layer (commercial): covers advanced drugs and premium services (20%+ annual growth).
• Safety net (medical aid): prevents poverty; rural copay under 30%.

The core challenge remains balancing efficiency with equity — particularly in creating payment pathways for innovative therapies while preserving pricing control. Pilot reforms (e.g., Hainan's specialty drug insurance, insurer-provider data sharing) are shaping China's unique multi-payer ecosystem.

Sources: NHSA Policy Documents (2023–2025), Provincial Health Commission Reports, WHO Health Financing Database.